ClinVar Miner

Submissions for variant NM_000257.4(MYH7):c.2155C>T (p.Arg719Trp) (rs121913637)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 14
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Inherited Cardiomyopathy Variant Curation Expert Panel, RCV000758071 SCV000564421 pathogenic Hypertrophic cardiomyopathy 2016-12-15 reviewed by expert panel curation The c.2155C>T (p.Arg719Trp) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:9829907; PMID:8282798; PMID:9822100; PMID:12974739; PMID:22429680; PMID:23816408; PMID:12707239; PMID:19645038; PMID:27532257; SHaRe consortium, PMID: 30297972; Partners LMM ClinVar SCV000059419.5 ), including 1 de novo occurrence (PS2; 10957787). This variant was found to segregate with disease in 8 affected family members (PP1_Strong; PMID:9829907; PMID:8282798; PMID:9822100; PMID:12974739; SHaRe consortium, PMID: 30297972). A mouse model indicates that this variant disrupts the function of MYH7 and leads to a phenotype consistent with HCM (PS3: PMID:24829265). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2156G>A p.Arg719Gln - Variation ID 14107). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS2; PS3; PS4; PP1_ Strong; PM1; PM2; PM5; PP3
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000758071 SCV000059419 pathogenic Hypertrophic cardiomyopathy 2019-02-22 criteria provided, single submitter clinical testing The p.Arg719Trp variant in MYH7 has been identified in >30 individuals with HCM (Treger 1965, Hejtmancik 1991, Anan 1994, Greve 1994, Jeschke 1998, Jääskeläinen 1998, Richard 2003, Jääskeläinen 2004, Poutanen 2006, Wang 2009, Santos 2012, Meyer 2013, Walsh 2017, Kelly 2018). In addition, it segregated with disease in >20 affected relatives from multiple families (Hejtmancik 1991, Anan 1994, Wang 2009, Guo 2017, LMM data) and was reported to have occurred de novo in 2 individuals (Greve 1994, Jeschke 1998). It has also been identified in 1/15430 European chromosomes by gnomAD (https://gnomad.broadinstitute.org). In vitro functional studies support an impact on protein function (Yamashita 2000, Kohler 2002, Seebohm 2009, Tripathi 2011). Other variants involving this codon, p.Arg719Gln and p.Arg719Pro, have also been associated with HCM. Of note, this variant lies in the head region of the protein. Missense variants in this region have been reported and statistically indicated to be more likely to cause disease (Walsh 2016). This variant was classified as pathogenic on 12/15/16 by the ClinGen-approved Inherited Cardiomyopathy Expert Panel (Variation ID 14104). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HCM. ACMG/AMP Criteria applied: PS4, PP1_Strong, PS2, PS3_Moderate, PM1, PM2, PM5, PP3.
GeneDx RCV000158512 SCV000208447 pathogenic not provided 2018-08-14 criteria provided, single submitter clinical testing The R719W pathogenic variant in the MYH7 gene has been reported multiple times in associationwith HCM (Anan et al., 1994; Jeschke et al., 1998; Richard et al., 2003; Erdmann et al., 2003; Frissoet al., 2009). Anan et al. (1994) reported the R719W variant co-segregated with HCM in affectedmembers of four unrelated families. The R179W variant has also been previously identified andconfirmed to have arisen de novo in a 8-year-old with HCM and personal history of sudden cardiacarrest (Jeschke et al., 1998). Additionally, the R179W variant has been seen in multiple individualsreferred for cardiomyopathy genetic testing at GeneDx, and is classified in ClinVar as a pathogenicvariant in association with HCM by multiple clinical laboratories (SCV000059419.4;SCV000219895.1; SCV000226727.1; SCV000280311.1; Landrum et al., 2016). R719W results in anon-conservative amino acid substitution of a positively charged Arginine with a non-polarTryptophan at a position where only amino acids with similar properties to Arginine are toleratedacross species. In addition, functional studies report the R719W variant appears to interfere with thenormal elastic response of the myosin head and could affect myosin cross-bridge function (Seebohm etal., 2009). Furthermore, other variants affecting the same residue (R719Q, R719P) and variants innearby residues (G716R, R723C, R723G, R723H) have been reported in HGMD in association withcardiomyopathy (Stenson et al., 2014), supporting the functional importance of this residue and thisregion of the protein. Moreover, R719W was not observed in approximately 6,500 individuals ofEuropean and African American ancestry in the the NHLBI Exome Sequencing Project, indicating it isnot a common benign variant in these populations.In summary, R719W in the MYH7 gene is interpreted as a pathogenic variant.
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000158512 SCV000226727 pathogenic not provided 2015-04-03 criteria provided, single submitter clinical testing
Ambry Genetics RCV000241836 SCV000318468 pathogenic Cardiovascular phenotype 2018-07-06 criteria provided, single submitter clinical testing Strong segregation with disease (lod >3 = >10 meioses)
Phosphorus, Inc. RCV000015160 SCV000679782 pathogenic Familial hypertrophic cardiomyopathy 1 2017-08-01 criteria provided, single submitter clinical testing
Blueprint Genetics RCV000158512 SCV000927157 pathogenic not provided 2017-02-18 criteria provided, single submitter clinical testing
Invitae RCV000758071 SCV000960592 pathogenic Hypertrophic cardiomyopathy 2019-12-17 criteria provided, single submitter clinical testing This sequence change replaces arginine with tryptophan at codon 719 of the MYH7 protein (p.Arg719Trp). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and tryptophan. This variant is not present in population databases (ExAC no frequency). This variant has been observed to be de novo in an individual affected with hypertrophic cardiomyopathy (PMID: 9544842), to segregate with this disease in families (PMID: 8282798), and reported in several unrelated individuals affected with this disease (PMID: 9822100, 16504640, 11904418, 19651039, 12707239, 21769673). ClinVar contains an entry for this variant (Variation ID: 14104). Experimental studies have shown that this missense change results in increased ATPase activity (PMID: 10882745) and increased muscle fiber cross-bridge stiffness (PMID: 11904418, 19651039). This variant disrupts the p.Arg719 amino acid residue in MYH7. Other variant(s) that disrupt this residue have been observed in affected individuals (PMID: 7848441, 23140321, 15358028, 15858117, 16199542, 18409188, 21896538, 10882745), suggesting that it is a clinically significant residue. As a result, variants that disrupt this residue are likely to be causative of disease. This variant is found within a region of MYH7 between codons 181 and 937 that contains the majority of the myosin head domain. Missense variants in this region have been shown to be significantly overrepresented in individuals with hypertrophic cardiomyopathy (PMID: 27532257). For these reasons, this variant has been classified as Pathogenic.
Agnes Ginges Centre for Molecular Cardiology,Centenary Institute RCV000758071 SCV001156298 pathogenic Hypertrophic cardiomyopathy 2018-09-27 criteria provided, single submitter research This variant has been identified in 3 HCM probands by our research program. For further information please feel free to contact us.
CHEO Genetics Diagnostic Laboratory,Children's Hospital of Eastern Ontario RCV001170501 SCV001333084 pathogenic Cardiomyopathy 2018-02-01 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV001194067 SCV001363323 pathogenic Primary familial hypertrophic cardiomyopathy 2019-09-24 criteria provided, single submitter clinical testing Variant summary: MYH7 c.2155C>T (p.Arg719Trp) results in a non-conservative amino acid change located in the Myosin head, motor domain (IPR001609) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251466 control chromosomes (gnomAD). c.2155C>T has been reported in the literature in multiple individuals affected with Hypertrophic Cardiomyopathy, with evidence of co-segregation with disease in multiple families and an observed association with high risk for premature death (e.g. Abchee_1997, Anan_1994, Kelly_2018, Poutanen_2006, Walsh_2017). These data indicate that the variant is very likely to be associated with disease. Nonrandom mutation cluster analysis revealed that rare MYH7 missense variants located between residues 181 and 937 have a statistically increased likelihood of being disease-associated (Walsh_2017). Experimental evidence evaluating an impact on protein function demonstrated that the variant significantly increased stiffness and force generation of the individual mutated myosin heads, resulting in reduced elastic distortion of the mutated myosin heads during isometric force generation (Seebohm_2009). Eight ClinVar submitters including an expert panel (ClinGen Inherited Cardiomyopathy Variant Curation Expert Panel) (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease,Montreal Heart Institute RCV000015160 SCV001433414 pathogenic Familial hypertrophic cardiomyopathy 1 2019-04-16 criteria provided, single submitter clinical testing
OMIM RCV000015160 SCV000035417 pathogenic Familial hypertrophic cardiomyopathy 1 1998-03-01 no assertion criteria provided literature only
Stanford Center for Inherited Cardiovascular Disease, Stanford University RCV000158512 SCV000280311 pathogenic not provided 2013-12-10 no assertion criteria provided clinical testing Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. This variant has been reported in at least 17 unrelated individuals with HCM (including the two patients in our center) with strong segregation data. Of note, there is data suggesting this variant is associated with a more severe phenotype and high penetrance. In our center we have seen the variant in two patients: a woman diagnosed with HCM at 14 years of age and a man diagnosed with HCM at 29 years of age. The variant was first reported by Greve et al (1994). Unfortunately that report is not available, though the title suggests the variant was de novo. The same group reported four unrelated families with p.Arg719Trp (Anan et al 1994). The authors note that all individuals with HCM in these three kindreds carried the variant. They don’t specify how many individuals were genotyped, though it seems that at least 9 were tested from one family and at least 12 in another, providing very strong segregation data. Jeschke et al (1998) reported a case of childhood-onset HCM and arrest with p.Arg719Trp, which arose de novo, and an additional MYH7 variant inherited from the unaffected mother (p.Met349Thr) (also reported in Dohlemann et al 2000). Paternity was confirmed. While maternity was not formally assesed, it is highly likely to be as reported given maternal inheritance of p.Met349Thr. Jaaskelainen et al (1998) observed the variant in three affected family members from their Finnish cohort. The proband’s mother did have some hypertrophy but was negative for the variant. Poutanen et al (2006) reported two children from the same family with p.Arg719Trp who both had wall thickness at the upper limits of normal, diastolic dysfunction, and pathological Q waves. Richard et al (2003) observed the variant in one individual in their French HCM cohort. Erdmann et al (2003) reported the variant segregating with HCM in two affected members of one family from their German cohort. Frisso et al (2009) observed the variant in three unrelated individuals from their Italian cohort. Santos et al (2012) observed this variant in one individual in their Portuguese cohort. GeneDx reports that p.Arg719Trp was observed in multiple additional unrelated individuals tested for HCM. This is a non-conservative amino acid change with a polar, positive Arginine replaced with a non polar, neutral Tryptophan. Mutationtaster and PolyPhen2 both predict the variant to be damaging. Arginine is conserved at this position across mammals. Other variants at the same codon (p.Arg719Gln (which we consider likely disease causing), p.Arg719Pro) and nearby codons (p.Gly716Arg, p.Arg721Lys, p.Arg712Leu, p.Gly716Arg, p.Arg723Cys, p.Arg723Gly, and p.Ala728Val have been reported in association with HCM (Harvard Sarcomere Protein Gene Mutation Database). Seebohm B et al (2009) demonstrated that the variant could interfere with myosin cross bridge function during contraction. Kohler et al (2002) observed an increase in force generation and fiber stiffness of muscle fibers with p.Arg719Trp and suggested that the cross-bridges were more resistant to elastic distortion. Anan et al (1994) suggested that this variant may be correlated with a particularly severe phenotype since the four families they studied with the variant had a particularly high frequency of disease-related deaths. Many of the initial genotype-phenotype correlations based on a handful of cases have since been called into question by the observation of mild disease in other families with the same variant, suggesting the initial observations may have been due to ascertainment bias. However, a recent paper from the same group found significantly earlier age of onset and age of first cardiac event in carriers of p.Arg719Trp as compared to carriers of MYBPC3 truncating variants or p.Arg502Trp in MYBPC3 (the most prevalent HCM-causing variant) (Saltzman et al 2010). All carriers had manifest disease by 30 years of age. It is unclear though, how many p.Arg719Trp carriers were included or how they were ascertained. Unfortunately many of the case reports reviewed above do not provide detailed data on severity, progression, or outcome. The variant was not observed in ~7000 published controls and publically available general population samples. GeneDx did not report internal control data. The variant is not listed in 1000 Genomes. There is no variation at codon 719 currently listed in the NHLBI Exome Sequencing Project dataset, which includes variant calls on approximately 6500 Caucasian and African American individuals (as of May 2014). Richard et al (2003) did not observe the variant in 100 controls. Frisso et al (2009) did not observe the variant in 200 controls with normal ECGs. Santos et al (2012) did not observe the variant in 100 healthy individuals.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.